Medicare Part B coverage and reimbursement issues for biotechnology treatments and issues related to the Medicare Part D coverage.
2025 · 1st Quarter (Jan 1 - Mar 31)
BIOTECHNOLOGY INNOVATION ORGANIZATION (FORMERLY BIOTECHNOLOGY INDUSTRY ORG.)
Filed by CAPITOL COUNSEL LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 18, 2025
- Income
- $140,000.00
- Expenses
- Not reported
- Registrant
- CAPITOL COUNSEL LLC
- Filing UUID
- 620ace0a-0a30-481d-af96-22f88fa61686
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Legislative and regulatory issues affecting innovation, including vaccines.
Issues related to tarriffs.
Items related to USDA, FDA, genetic engineering, and regulations associated with biotechnology in the Agriculture/Rural Development/Food and Drug Administration proposed Appropriation measures for FY 2026 (House/Senate).
Public health issues impacting patient access to treatments. Updates and reforms to regulation of treatment development and research.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.